Wells Fargo & Company Intellia Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 215,758 shares of NTLA stock, worth $5.81 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,758
Previous 202,594
6.5%
Holding current value
$5.81 Million
Previous $6.18 Million
3.92%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NTLA
# of Institutions
322Shares Held
89.8MCall Options Held
691KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$312 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$245 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$245 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$124 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$113 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $2.05B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...